Adriamycin, Vincristine and Prednisone in the Treatment of Malignant Tumors Resistant to Conventional Chemotherapy
Adriamycin (14-hydroxy-daunorubicine), a new cytotoxic antibiotic isolated from cultures of streptomyces peuceticus var. caesius, was introduced to clinical chemotherapy of human neoplasms in 1969 by Bonadonna and co-workers . The drug seems to have significant antitumor activity in a much larger spectrum of malignant diseases than daunorubicine, especially in solid tumors [1-3]. It has mainly been used as a single agent. It was the aim of this study to explore antitumor effect and toxicity of the combination chemotherapy with adriamycin, vincristine and prednisone.
KeywordsAcute Myelocytic Leukemia Acute Lymphocytic Leukemia Combination Chemotherapy Conventional Chemotherapy Cytosine Arabinoside
Unable to display preview. Download preview PDF.